Compare BGC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGC | LQDA |
|---|---|---|
| Founded | 1945 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.5B |
| IPO Year | 1999 | 2020 |
| Metric | BGC | LQDA |
|---|---|---|
| Price | $11.54 | $85.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | ★ 2.3M | 1.4M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | 24.00 | ★ 51.81 |
| EPS | 0.17 | ★ 0.52 |
| Revenue | ★ $2,941,460,000.00 | $158,320,000.00 |
| Revenue This Year | $22.26 | $278.87 |
| Revenue Next Year | $7.03 | $57.13 |
| P/E Ratio | ★ $69.21 | $167.10 |
| Revenue Growth | 29.99 | ★ 1031.18 |
| 52 Week Low | $8.27 | $17.82 |
| 52 Week High | $12.89 | $91.10 |
| Indicator | BGC | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 53.45 | 59.67 |
| Support Level | $10.47 | $70.28 |
| Resistance Level | $11.91 | $91.10 |
| Average True Range (ATR) | 0.32 | 5.47 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 59.43 | 71.85 |
BGC Group Inc is a brokerage and financial technology company that serves financial markets, energy, and commodities markets. Its service and product offerings include brokerage for a wide range of financial products, including fixed income, equities, commodities, derivatives, and real estate, software solutions for trading platforms, clearing, trade execution, and other back-office services. Its clients mostly include banks, financial institutions, and corporate clients. BGC operates in one reportable segment, which is providing brokerage services. Geographically, the company generates a majority of its revenue from Europe, the Middle East and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.